Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

46.63 +0.69 (+1.51%)

Streaming Delayed Price Updated: 1:49 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

82 83 Next >

S&P 500 Earnings Dashboard 24Q1 - Saturday, June 22 ↗

June 22, 2024

Of the 498 companies in the S&P 500 that have reported earnings to date for 24Q1, 78.7% reported above analyst expectations. This compares to a long-term average of 66%.

Via Talk Markets

Topics Stocks

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

June 22, 2024

You won't need much money to start investing in these great stocks.

Via The Motley Fool

3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold ↗

June 22, 2024

The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.

Via The Motley Fool

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

June 21, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over? ↗

June 19, 2024

Technical analysis suggests short-term support at $39.90; potential recovery to $56.

Via Talk Markets

This Is What Whales Are Betting On Bristol-Myers Squibb ↗

June 18, 2024

Via Benzinga

Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗

June 10, 2024

Via Benzinga

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗

June 21, 2024

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.

Via Benzinga

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

June 21, 2024

From Bristol Myers Squibb

Via Business Wire

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount ↗

June 20, 2024

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

Via Benzinga

Smart Money Is Betting Big In BMY Options ↗

June 07, 2024

Via Benzinga

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

June 20, 2024

From Bristol Myers Squibb

Via Business Wire

3 Warren Buffett Stocks to Buy Now: June 2024 ↗

June 19, 2024

If you have a long-term view of the market, it’s a good time to look for some Warren Buffett stocks to buy now.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

June 19, 2024

Via Benzinga

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

June 18, 2024

From Bristol Myers Squibb

Via Business Wire

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb ↗

June 18, 2024

These two pharma stocks are beloved by income investors.

Via The Motley Fool

Bristol Myers Squibb Announces Dividend

June 18, 2024

From Bristol Myers Squibb

Via Business Wire

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗

June 17, 2024

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.

Via InvestorPlace

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade ↗

June 15, 2024

Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily.

Via The Motley Fool

Topics Stocks

3 High-Yield Dividend Stocks for Income Now and Growth Later

June 14, 2024

Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year

Via MarketBeat

Topics Economy

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

June 13, 2024

From Bristol Myers Squibb

Via Business Wire

3 Penny Stocks to Buy if You Want to Spend Less and Earn More ↗

June 11, 2024

These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential.

Via InvestorPlace

7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too) ↗

June 10, 2024

Here are seven Warren Buffett stocks to sell that the Oracle himself has decided that they've lost their luster.

Via InvestorPlace

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 ↗

June 08, 2024

Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder

Via InvestorPlace

FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug ↗

June 07, 2024

FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market...

Via Benzinga

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? ↗

June 06, 2024

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was...

Via Benzinga

Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients ↗

June 04, 2024

Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

82 83 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today